Illumina, Inc. (FRA:ILU)
Market Cap | 11.22B |
Revenue (ttm) | 4.00B |
Net Income (ttm) | -891.81M |
Shares Out | n/a |
EPS (ttm) | -5.61 |
PE Ratio | n/a |
Forward PE | 18.75 |
Dividend | 2.89 (4.02%) |
Ex-Dividend Date | Jun 25, 2024 |
Volume | 3 |
Average Volume | 156 |
Open | 69.93 |
Previous Close | 70.39 |
Day's Range | 69.93 - 70.00 |
52-Week Range | 62.29 - 146.32 |
Beta | n/a |
RSI | 48.80 |
Earnings Date | May 8, 2025 |
About Illumina
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.
Financial numbers in USD Financial StatementsNews

Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, an...

Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn is making bold moves from the lab to the tarmac.
Carl Icahn boosts stakes in CVR Energy, JetBlue, Illumina, among Q1 trades
Illumina stock rises after executives disclose stock purchase

Quantum-Si (QSI) Earnings Coverage: Complete 1Q Coverage
Live Updates Live Coverage Updates appear automatically as they are published. QSI Earnings Backdrop 11:26 am Quantum-Si operates at the intersection of biotech instrumentation and proteomics, targeti...

Illumina To Webcast Upcoming Investor Conference
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: 41st Annual Bernstein Strategic Decisi...

Illumina DRAGEN v4.4 powers clinical oncology research and multiomic applications
Building on reputation for unparalleled performance, latest software delivers even greater accuracy, with 30% improvement in structural variant calling New features include easy-to-use oncology apps, ...

Illumina Analysts Lower Their Forecasts After Q1 Results
Illumina, Inc. (NASDAQ: ILMN) reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday. The company posted quarterly earnings of 97 cents per ...

Illumina Analysts Lower Their Forecasts After Q1 Results
Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.
Illumina: Multiple Headwinds Point To Limited Upside In 2025
Illumina outlines $4.18B to $4.26B guidance for 2025 amid China headwinds and strategic cost reductions
Illumina, Inc. (ILMN) Q1 2025 Earnings Call Transcript
Illumina down 3% as lowered 2025 EPS guidance overshadows Q1 top-line beat

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
First real-world dataset with integrated clinical and multiomic insights from 25,000 patients treated with GLP-1 therapies Dataset will advance development of GLP-1 therapies in new indications and ac...
Rep. Thomas Kean Has Bought Up to $45K Worth Of Illumina Stock: Here's What You Should Know
April 18, 2025 records indicate that Representative Thomas Kean filed a purchase of Illumina (NASDAQ: ILMN), valued between $3,003 and $45,000. According to the April filing, the transaction occurred...

Target Validation for Genetic Targets Innovation Research Report 2025: 14,172 Deals Totaling $11.4 Billion - BGI biotech and illumina are Among the Leaders with Strong Portfolios
Dublin, April 18, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: Target validation for genetic targets" report has been added to ResearchAndMarkets.com's offering.

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO , April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN...

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
SAN DIEGO , April 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8, 2025. O...
Snowflake Unveils Apache Iceberg™ Innovations, Giving Enterprises the Best of Open Data and AI-Ready Performance
Customers now get the best of both worlds: Iceberg’s flexibility and interoperability coupled with Snowflake’s powerful platform to make their data easy, connected, and trusted Thousands of customers ...

Apple To $250? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Citigroup...

Corvexs Meister joins the board at Illumina. Heres how he can create value for shareholders
Keith Meister, Corvex Management's chief investment officer, will join Illumina's board starting March 28. He's no stranger to the world of biotech.
Is Illumina Undervalued After An 83% Drop In Its Stock Price?
Illumina rises after board revamp

Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors
Stephen MacMillan to retire from the Board SAN DIEGO , March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced cha...

Activist investor Keith Meister to join Illumina's board, WSJ reports
Activist investor Keith Meister will join the board of gene-sequencing maker Illumina , and current board member Scott Gottlieb will become chairman, the Wall Street Journal reported on Tuesday, citin...